Payment overview · 2025
General Payments
$797.24
32 reported records · 10 companies
Healthcare provider profile · identity verified
Jose Pinal, MD
Allopathic & Osteopathic Physicians|Internal Medicine · UNION CITY, NJ · NPI 1013098862
Verified facts
What the public records show
CMS Open Payments records show Jose Pinal, MD received $797.24 in general payments during 2025 across 32 reported records.
GlaxoSmithKline, LLC. accounted for 49.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Jardiance, Linzess, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 291 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $390.98 | 49.0% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $177.19 | 22.2% | 9 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $47.61 | 6.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.94 | 5.4% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.93 | 3.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $25.13 | 3.1% | 1 | 2025 |
| INOGEN, INC. | Unresolved — no canonical attribution shown | $24.14 | 3.0% | 1 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $21.32 | 2.7% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $19.50 | 2.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.50 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $797.24 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $168.20 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $118.39 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $104.39 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $75.34 | 4 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $53.47 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $48.38 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $47.61 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $42.94 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $30.93 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $30.93 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $25.13 | 1 | 2025 |
Source payment records
|
|||||
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | INOGEN, INC. | $24.14 | 1 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $21.32 | 1 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $21.32 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $21.32 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $21.32 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $19.50 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 90 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 70 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 291 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
90 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
36 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
19 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
70 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
291 | 77 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 420 | 80 |
| Atorvastatin Calcium | Atorvastatin Calcium | 401 | 61 |
| Mirtazapine | Mirtazapine | 367 | 46 |
| Amlodipine Besylate | Amlodipine Besylate | 359 | 52 |
| Metformin Hcl | Metformin Hcl | 346 | 49 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 291 | 77 |
| Metoprolol Tartrate | Metoprolol Tartrate | 288 | 35 |
| Eliquis | Apixaban | 268 | 27 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 256 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 246 | 36 |
| Montelukast Sodium | Montelukast Sodium | 245 | 57 |
| Memantine Hcl | Memantine Hcl | 238 | 28 |
| Omeprazole | Omeprazole | 238 | 39 |
| Alprazolam | Alprazolam | 231 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 224 | 25 |
| Furosemide | Furosemide | 212 | 29 |
| Januvia | Sitagliptin Phosphate | 208 | 16 |
| Divalproex Sodium | Divalproex Sodium | 193 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 185 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 185 | 45 |
| Carvedilol | Carvedilol | 179 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 178 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 164 | 34 |
| Sertraline Hcl | Sertraline Hcl | 164 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 160 | 39 |
| Donepezil Hcl | Donepezil Hcl | 151 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 151 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 143 | suppressed |
| Ezetimibe | Ezetimibe | 141 | 23 |
| Meclizine Hcl | Meclizine Hcl | 140 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 134 | 23 |
| Vascepa | Icosapent Ethyl | 129 | 24 |
| Lactulose | Lactulose | 120 | 25 |
| Levetiracetam | Levetiracetam | 120 | 11 |
| Gabapentin | Gabapentin | 118 | 16 |
| Finasteride | Finasteride | 117 | suppressed |
| Simvastatin | Simvastatin | 110 | 13 |
| Glimepiride | Glimepiride | 106 | 21 |
| Potassium Chloride | Potassium Chloride | 103 | 16 |
| Valsartan | Valsartan | 100 | 22 |
| Azithromycin | Azithromycin | 99 | 61 |
| Xarelto | Rivaroxaban | 94 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 94 | 17 |
| Losartan Potassium | Losartan Potassium | 93 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 91 | 11 |
| Clonidine Hcl | Clonidine Hcl | 90 | 11 |
| Creon | Lipase/Protease/Amylase | 90 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 84 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 84 | 11 |
| Alendronate Sodium | Alendronate Sodium | 83 | suppressed |
| Lisinopril | Lisinopril | 77 | 14 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 73 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 72 | suppressed |
| Jardiance | Empagliflozin | 70 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 69 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 61 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 59 | 14 |
| Ozempic | Semaglutide | 56 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 55 | suppressed |
| Pregabalin | Pregabalin | 54 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 53 | 15 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 49 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | 16 |
| Latanoprost | Latanoprost | 49 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 49 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 47 | 13 |
| Ammonium Lactate | Ammonium Lactate | 46 | suppressed |
| Famotidine | Famotidine | 45 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 15 |
| Mometasone Furoate | Mometasone Furoate | 44 | 11 |
| Azelastine Hcl | Azelastine Hcl | 43 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 41 | suppressed |
| Irbesartan | Irbesartan | 39 | 11 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 39 | suppressed |
| Lorazepam | Lorazepam | 38 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 38 | 14 |
| Hydrocortisone | Hydrocortisone | 37 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 37 | 12 |
| Linzess | Linaclotide | 37 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 22 |
| Farxiga | Dapagliflozin Propanediol | 36 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 12 |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Naproxen | Naproxen | 35 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Risperidone | Risperidone | 34 | suppressed |
| Ketoconazole | Ketoconazole | 33 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 21 |
| Diltiazem Hcl | Diltiazem Hcl | 32 | suppressed |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 29 | 11 |
| Trulicity | Dulaglutide | 29 | suppressed |
| Ibuprofen | Ibuprofen | 28 | 14 |
| Icosapent Ethyl | Icosapent Ethyl | 28 | 15 |
| Memantine Hcl Er | Memantine Hcl | 28 | suppressed |
| Prednisone | Prednisone | 28 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Mupirocin | Mupirocin | 27 | 16 |
| Restasis | Cyclosporine | 27 | suppressed |
| Alogliptin | Alogliptin Benzoate | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 19 |
| Nystatin | Nystatin | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Clonidine | Clonidine | 24 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 24 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Cilostazol | Cilostazol | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Allopurinol | Allopurinol | 22 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 22 | suppressed |
| Repatha Sureclick | Evolocumab | 22 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Cyclosporine | Cyclosporine | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Lamotrigine Odt | Lamotrigine | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 13 |
| Lidocaine | Lidocaine | 20 | suppressed |
| Procto-Med Hc | Hydrocortisone | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 19 | 12 |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 18 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 18 | suppressed |
| Insulin Lispro | Insulin Lispro | 18 | suppressed |
| Meloxicam | Meloxicam | 18 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 18 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Lubiprostone | Lubiprostone | 17 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 16 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 16 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Pentoxifylline | Pentoxifylline | 16 | suppressed |
| Procrit | Epoetin Alfa | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Nateglinide | Nateglinide | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Zonisamide | Zonisamide | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 13 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 12 | suppressed |
| Epogen | Epoetin Alfa | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Silodosin | Silodosin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $797.24 · 32 records | GlaxoSmithKline, LLC. | AIRSUPRA, AREXVY, BREZTRI, CHARTIS CATHETER, CREON, Cologuard Collection Kit, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, JARDIANCE, Kerendia, LINZESS, NUCALA, OTEZLA, Ohtuvayre, PULMONX CHARTIS TABLET CONSOLE, REPATHA, TEZSPIRE, TRELEGY ELLIPTA, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error